Pre-publication history
Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group
-
* Corresponding author: Howard Trachtman trachtma@lij.edu
BMC Nephrology 2010, 11:2 doi:10.1186/1471-2369-11-2
Pre-publication versions of this article and reviewers' reports
| Original Submission - Version 1 | Manuscript | 02 Oct 2009 | |
| Reviewer's Report | Pankaj Hari | 16 Nov 2009 | |
| Reviewer's Report | Therese Jungraithmayr | 20 Nov 2009 | |
| Resubmission - Version 2 | Manuscript | Author's comment | 02 Dec 2009 |
| Resubmission - Version 3 | Manuscript | Author's comment | 03 Dec 2009 |
| Reviewer's Report | Pankaj Hari | 21 Dec 2009 | |
| Reviewer's Report | Therese Jungraithmayr | 22 Dec 2009 | |
| Resubmission - Version 4 | Manuscript | Author's comment | 15 Jan 2010 |
| Editorial acceptance | 20 Jan 2010 | ||
| Published | 29 Jan 2010 |